Cargando…
Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy
The incidence of contralateral prophylactic mastectomy (CPM) has increased among women with breast cancer, despite uncertain survival benefit and a declining incidence of contralateral breast cancer (CBC). Patient-related reasons for undergoing CPM include an overestimation of the risk of CBC, incre...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324540/ https://www.ncbi.nlm.nih.gov/pubmed/25678823 http://dx.doi.org/10.2147/IJWH.S52380 |
_version_ | 1782356695438065664 |
---|---|
author | Davies, Kalatu R Cantor, Scott B Brewster, Abenaa M |
author_facet | Davies, Kalatu R Cantor, Scott B Brewster, Abenaa M |
author_sort | Davies, Kalatu R |
collection | PubMed |
description | The incidence of contralateral prophylactic mastectomy (CPM) has increased among women with breast cancer, despite uncertain survival benefit and a declining incidence of contralateral breast cancer (CBC). Patient-related reasons for undergoing CPM include an overestimation of the risk of CBC, increased cancer worry, and a desire to improve survival. We summarize the existing literature on CBC risk and outcomes and the clinical benefit of CPM among women with unilateral breast cancer who have a low-to-moderate risk of developing a secondary cancer in the contralateral breast. Published studies were retrieved from the MEDLINE database with the keywords “contralateral breast cancer” and “contralateral prophylactic mastectomy”. These include observational studies, clinical trials, survival analyses, and decision models examining the risk of CBC, the clinical and psychosocial effects of CPM, and other treatment strategies to reduce CBC risk. Studies that have evaluated CBC risk estimate it to be approximately 0.5% annually on average. Patient-related factors associated with an increased risk of CBC include carriers of BRCA1/2 mutations, young age at breast cancer, and strong family history of breast cancer in the absence of a BRCA1/2 mutation. Although CPM reduces the risk of CBC by approximately 94%, it may not provide a significant gain in overall survival and there is conflicting evidence that it improves disease-free survival among women with breast cancer regardless of estrogen receptor (ER) status. Therefore, alternative strategies such as the use of tamoxifen or aromatase inhibitors, which reduce the risk of CBC by approximately 50%, should be encouraged for eligible women with ER-positive breast cancers. Future research is needed to evaluate the impact of decision and educational tools that can be used for personalized counseling of patients regarding their CBC risk, the uncertain role of CPM, and alternative CBC risk reduction strategies. |
format | Online Article Text |
id | pubmed-4324540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43245402015-02-12 Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy Davies, Kalatu R Cantor, Scott B Brewster, Abenaa M Int J Womens Health Review The incidence of contralateral prophylactic mastectomy (CPM) has increased among women with breast cancer, despite uncertain survival benefit and a declining incidence of contralateral breast cancer (CBC). Patient-related reasons for undergoing CPM include an overestimation of the risk of CBC, increased cancer worry, and a desire to improve survival. We summarize the existing literature on CBC risk and outcomes and the clinical benefit of CPM among women with unilateral breast cancer who have a low-to-moderate risk of developing a secondary cancer in the contralateral breast. Published studies were retrieved from the MEDLINE database with the keywords “contralateral breast cancer” and “contralateral prophylactic mastectomy”. These include observational studies, clinical trials, survival analyses, and decision models examining the risk of CBC, the clinical and psychosocial effects of CPM, and other treatment strategies to reduce CBC risk. Studies that have evaluated CBC risk estimate it to be approximately 0.5% annually on average. Patient-related factors associated with an increased risk of CBC include carriers of BRCA1/2 mutations, young age at breast cancer, and strong family history of breast cancer in the absence of a BRCA1/2 mutation. Although CPM reduces the risk of CBC by approximately 94%, it may not provide a significant gain in overall survival and there is conflicting evidence that it improves disease-free survival among women with breast cancer regardless of estrogen receptor (ER) status. Therefore, alternative strategies such as the use of tamoxifen or aromatase inhibitors, which reduce the risk of CBC by approximately 50%, should be encouraged for eligible women with ER-positive breast cancers. Future research is needed to evaluate the impact of decision and educational tools that can be used for personalized counseling of patients regarding their CBC risk, the uncertain role of CPM, and alternative CBC risk reduction strategies. Dove Medical Press 2015-02-04 /pmc/articles/PMC4324540/ /pubmed/25678823 http://dx.doi.org/10.2147/IJWH.S52380 Text en © 2015 Davies et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Davies, Kalatu R Cantor, Scott B Brewster, Abenaa M Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy |
title | Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy |
title_full | Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy |
title_fullStr | Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy |
title_full_unstemmed | Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy |
title_short | Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy |
title_sort | better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324540/ https://www.ncbi.nlm.nih.gov/pubmed/25678823 http://dx.doi.org/10.2147/IJWH.S52380 |
work_keys_str_mv | AT davieskalatur bettercontralateralbreastcancerriskestimationandalternativeoptionstocontralateralprophylacticmastectomy AT cantorscottb bettercontralateralbreastcancerriskestimationandalternativeoptionstocontralateralprophylacticmastectomy AT brewsterabenaam bettercontralateralbreastcancerriskestimationandalternativeoptionstocontralateralprophylacticmastectomy |